Compare Corsair Gaming Inc (CRSR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Recursion Pharmaceuticals Inc — how do they compare? Corsair Gaming Inc trades at $13.49 (market cap $1.42B), while Recursion Pharmaceuticals Inc trades at $4.31 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CRSR | RXRX | |
|---|---|---|
Market Cap | $1.42B | $2.14B |
Volume | 1,160,938 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $14.35 | $6.79 |
52-Week Low | $4.58 | $2.84 |
Typical Hold Time | 25 Days | 22 Days |
Enterprise Value | $1.41B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSR trades at $13.1, down 3.61% today, with a bullish technical signal from moving averages and a neutral RSI. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.23 versus $0.07 expected. The company reported a net loss of $16.16 million in 2025 but forecasts a profit of $37 million for 2026. Positive developments include new product launches like the VOXARA microphone and strategic acquisitions such as Trak Racer assets.
The outlook is mixed; strong earnings beats and product innovation support growth, but high P/E of 42.23 and recent net losses pose valuation and profitability risks. Analyst consensus is a 'Hold' with a $12.40 price target, slightly below the current price, indicating cautious optimism amid execution challenges.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
